Send to

Choose Destination
Infect Disord Drug Targets. 2018 Nov 25. doi: 10.2174/1871526519666181126094244. [Epub ahead of print]

Repurposing of existing drugs for the bacterial infections: An In silico and In vitro study.

Author information

Department of Biotechnology, ISF Institute of Professional Studies (ISFIPS), Moga, Punjab. India.
Department of Pharmacology, ISF College of Pharmacy (ISFCP), Moga, Punjab. India.



The emergence of infectious diseases and its resistance to approved drugs is a global threat to human health. The incidence of infectious diseases is increasing day by day and expected to rise exponentially in next 2 decades. Thus, there is a need for new treatment modalities for the treatment of microbial infections.


Thus, in the current investigation, we have explored the existing drugs [metformin (Anti-diabetic), propranolol (Anti-hypertensive), and amitriptyline (antidepressant)] for treatment of infectious diseases.


An in-silico result of current investigation has shown the good interaction of metformin, propranolol, and amitriptyline towards various targets (Beta-lactamase, Penicillin-binding proteins, Staphylokinase protein, Oxidoreductase protein, etc.) of gram positive and gram negative bacteria as that of internal ligand. Further, in-vitro results have shown that the antibacterial activity of metformin, propranolol, and amitriptyline against Bacillus pumilus, Pseudomonas aeruginosa and Staphylococcus aureus.


The parameters such as Microtiter assay: percentage growth retardation and bacterial growth kinetics, Minimum inhibitory concentration (MIC), Post-antibiotic assay and Biofilm formation have indicated the antibacterial potential of metformin, propranolol, and amitriptyline. However, before starting a clinical trial, complete safety and efficacy profile of drugs in the treatment of infectious diseases should be investigated.


Drug repurposition; In silico; In vitro studies; Infectious diseases

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center